Introduction
Disclosures
Objectives
Most Common Cancers in Women
Cancer Susceptibility Syndromes
Causes of Hereditary Susceptibility Ovarian Cancer
Who Is at Inherited Risk?
Tumor Suppressor Genes
Possible Hereditary Cancer Syndrome
Hereditary vs. Sporadic Breast Cancer
Assess Family History
Family History Screen
Hereditary Breast-Ovarian Cancer Syndrome
BRCA1-Associated Cancers
BRCA2-Associated Cancers
Which Patients Should be Referred for Genetic Counseling?
ACOG Practice Bulletin #103
ACOG Practice Bulletin #103 (2)
Prevalence of Germline BRCA Mutations in Ovarian Cancer
Prevalence of Germline BRCA Mutations Triple Neg Breast Cancer
Hereditary Cancer Risk Assessment is a Process
Risk-Reduction Strategies
Intensive Surveillance
Mammogram Screening
MRI Breast Screening
Prospective Studies of MRI Screening for Breast Cancer
Stage Shift – Breast MRI
Chemoprevention
Oral Contraceptives: Impact on Ovarian Cancer Risk
Oral Contraceptives: Impact on Breast Cancer Risk
Risk-Reducing Surgery
Risk-Reducing Salpingo-Oophorectomy I
Risk-Reducing Salpingo-Oophorectomy II
Mutations in BRCA1 and BRCA2
Risk of BRCA-associated Gynecologic Cancer
Risk of BRCA-associated Breast Cancer
Impact of RRSO on ER-positive vs. ER-negative
Surgical Considerations
Primary Peritoneal Cancer
RRSO I
RRSO II
Prevalence of Occult Cancer
What is SEE-FIM?
Timing of Procedure
What is the Role of HRT?
HRT following RRSO
What has RRSO Taught Us?
Ovarian Tumorigenesis – 2002
Ovarian Cancer Tumorigenesis 2013
What is the Role of Risk-Reducing Salpingectomy?
Is it Reasonable to Remove Just the Fallopian Tubes for Risk-Reduction?
Challenges for the Future I
Challenges for the Future II
Acknowledgements
1 of 54